Nicchia E, Giordano P, Greco C, De Rocco D, Savoia A
Department of Medical Sciences, University of Trieste, Trieste, Italy.
University of Bari, Bari, Italy.
Int J Lab Hematol. 2016 Aug;38(4):412-8. doi: 10.1111/ijlh.12516. Epub 2016 Jun 20.
Thrombocytopenia-absent radius (TAR) syndrome is a rare autosomal recessive disease. Patients are compound heterozygotes for a loss-of-function allele, which in most cases is a large genomic deletion on chromosome 1q21.1 containing the RBM8A gene, and a noncoding variant located in the 5'UTR (rs139428292) or intronic (rs201779890) regions of RBM8A. As the molecular genetic testing in TAR requires multiple techniques for detection of copy-number variations (CNV) and nucleotide substitutions, we tested whether a next-generation sequencing (NGS) approach could identify both alterations.
Two unrelated families were analyzed with Ion PGM sequencing using a target panel of genes responsible for different forms of inherited thrombocytopenia. A statistical quantitative evaluation of amplicon coverage was performed to detect CNV, in particular those on the RBM8A gene.
All the probands were apparently homozygous for the rare allele inherited by the father at the rs139428292 locus, suggesting the presence of a deletion on the maternal chromosome. The statistical analysis confirmed the hemizygous condition of RBM8A.
We concluded that NGS approaches could be used as a cost-effective method for molecular investigation of TAR as they could simultaneously detect CNV and point mutations.
血小板减少伴桡骨缺失(TAR)综合征是一种罕见的常染色体隐性疾病。患者是功能丧失等位基因的复合杂合子,在大多数情况下,该等位基因是1q21.1染色体上包含RBM8A基因的大片段基因组缺失,以及位于RBM8A基因5'非翻译区(rs139428292)或内含子区(rs201779890)的非编码变异。由于TAR的分子遗传学检测需要多种技术来检测拷贝数变异(CNV)和核苷酸替换,我们测试了下一代测序(NGS)方法是否能同时识别这两种改变。
使用针对不同形式遗传性血小板减少症相关基因的靶向panel,通过Ion PGM测序对两个无关家族进行分析。对扩增子覆盖度进行统计定量评估以检测CNV,特别是RBM8A基因上的CNV。
所有先证者在rs139428292位点上由父亲遗传的罕见等位基因显然是纯合的,这表明母源染色体上存在缺失。统计分析证实了RBM8A的半合子状态。
我们得出结论,NGS方法可作为一种经济有效的方法用于TAR的分子研究,因为它们可以同时检测CNV和点突变。